🎯 Drug Targets

Browse 7 drug targets with druggability analysis, composite scores, and clinical context

7

Targets

0

High Druggability

0.55

Avg Score

15

Target Classes

Druggability Distribution

High: 0Medium: 0Low: 7Unknown: 0

Avg druggability score: 0.377

Clinical Pipeline

Approved: 3Phase III: 1Phase II: 2Phase I: 1Preclinical: 0

Total compounds: 9 · Approved: 3

Filtered by: class=ligand, druggability=Low — 7 results

BDNF Brain Derived Neurotrophic Factor Phase II

Ligand Low Druggability

Protein replacement therapy or small molecule mimetic

ANGPT1 Angiopoietin-1 Approved

Ligand Low Druggability

Protein therapeutics or small molecule mimetics activating Tie2 signaling

TGFB1 Transforming growth factor beta-1 Phase III

Ligand Low Druggability

Monoclonal antibodies neutralizing TGF-β1 or small molecule inhibitors of TGF-β signaling

CRH Corticotropin Releasing Hormone Approved

Ligand Low Druggability

CRH receptor antagonist blocking stress hormone signaling

NTN1 Netrin-1 Phase I

Ligand Low Druggability

Modulation of axon guidance and neuronal survival pathways

IL10 Interleukin-10 Phase II

Ligand Low Druggability

Recombinant protein replacement or monoclonal antibody modulation

SST Somatostatin Approved

Ligand Low Druggability

Somatostatin is a peptide neurotransmitter that modulates neuronal signaling by inhibiting hormone release and neuronal excitability, with emerging evidence suggesting its potential neuroprotective role in neurodegenerative processes through regulation of inflammatory responses and synaptic plasticity. In neurodegeneration contexts, SST receptors may serve as modulators of neuroinflammatory cascades and potentially mitigate progressive neuronal damage through receptor-mediated signaling mechanisms.